The FDA just approved a new nasal application for allergy medicine. Pennsylvania law allows for school nurses to train other ...

The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal spray, Valtoco, for the short-term treatment of acute repetitive seizures, also referred to as seizure clusters ...

Previously called STS101, the company said Wednesday that the drug’s brand name is Atzumi and is indicated for acute migraine ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

Nasal spray offers an alternative for patients ... this is exactly the response required.” As part of the approval process, the FDA asked Belhaven Biopharma to determine if one dose of Nasdepi ...

Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved VALTOCO® (diazepam nasal spray) for short-term treatment of seizure clusters (also known as "acute repetitive ...

If you have seasonal allergies, you might be miserable when springtime rolls around. As the temperatures warm and the flowers ...

Note: After the FDA approves a drug ... for an upper respiratory infection or allergy. Because these are also nasal sprays, it is important to take these medicines at least 1 hour before taking ...

The recommended dose of Atzumi is 5.2 mg, the contents of 1 nasal device, administered into 1 nostril. The Food and Drug Administration (FDA) has approved Atzumi ™ (dihydroergotamine ...